Tixel Treatment for Dry Eye Symptoms
Primary Purpose
Peri-orbital Wrinkles, Dry Eye
Status
Completed
Phase
Not Applicable
Locations
Andorra
Study Type
Interventional
Intervention
Tixel
Sponsored by
About this trial
This is an interventional treatment trial for Peri-orbital Wrinkles
Eligibility Criteria
Inclusion Criteria:
- ≥ 18 years
- Mild to Moderate Periorbital wrinkles
- OSDI score of at least 23
- Noninvasive Tear film break up time (NIKBUT) ≤ 10 seconds
- Willing and able to provide written informed consent.
- Willing to participate in all study activities and instructions.
Exclusion Criteria:
- Pregnancy and breastfeeding
- Lesions in the periorbital area
- Acute severe blepharitis
- Acute conjunctivitis
- Other concomitant anterior eye disease
Sites / Locations
- Vallmedic Vision & Aesthetic
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Tixel Group
Arm Description
Tixel treatments in Dry Eye Patients
Outcomes
Primary Outcome Measures
Safety, Device related AE frequency in the study
Any safety related event during the study will be recorded and analysed
NIBUT in Seconds
Non-Invasive Break Up Time
Secondary Outcome Measures
Efficacy assessment - OSDI-Ocular Surface Disease Index Questionnaire changes from baseline
OSDI Score; 12 Questions; answers between 0-4; Total score calculated 0-100. Higher score means worst Dry Eye Symptomes
Osmolarity mOsml/L
Osmolarity test with TearLab
Staining; Total Ocular Staining Score
Corneal staining fluorescein and conjunctival/lid margin staining lissamine green
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05299619
Brief Title
Tixel Treatment for Dry Eye Symptoms
Official Title
A Prospective Study Assessing the Impact of Tixel Treatment of Peri-orbital Wrinkles on Dry Eye Symptoms and Signs in Patients With Dry Eye
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
March 28, 2019 (Actual)
Primary Completion Date
February 22, 2022 (Actual)
Study Completion Date
March 28, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dr Ludger Hanneken
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. Meibomian Gland Dysfunction (MGD) refers to the condition where the glands are not secreting enough oil or when the oil they secrete is of poor quality.
Tixel is a fractional skin rejuvenation system, which relies on direct thermal energy delivery, free of any radiation type such as laser, RF, etc. The energy is transferred via a continuously sterile, thermal titanium element (the "Tip"), located on the applicator (the "Handpiece"). In this study, the principal investigator will undertake standard treatment of periorbital wrinkles with Tixel and observe the effect on dry eye disease symptoms and signs.
Detailed Description
Tixel® (Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation). The system consists of a handpiece connected to a console. The handpiece applies a therapeutic element, the "tip", fixated on the distal section. The tip is comprised of a gold-plated copper base and a thin-walled titanium alloy cover.
While treating patients for wrinkles, it has been observed that in several cases, treatment had an effect on subjects who have been suffering from a pre-condition of dry eye disease. The effect was expressed mainly by increased tearing.
In this study, the principal investigator will undertake standard treatment of periorbital wrinkles with Tixel and observe the effect on dry eye disease symptoms and signs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peri-orbital Wrinkles, Dry Eye
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
A single-center, prospective, non-masked, pilot study, to assess the safety and efficacy of the Tixel treatment.
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Tixel Group
Arm Type
Experimental
Arm Description
Tixel treatments in Dry Eye Patients
Intervention Type
Device
Intervention Name(s)
Tixel
Other Intervention Name(s)
thermomechanical system
Intervention Description
a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
Primary Outcome Measure Information:
Title
Safety, Device related AE frequency in the study
Description
Any safety related event during the study will be recorded and analysed
Time Frame
8 months
Title
NIBUT in Seconds
Description
Non-Invasive Break Up Time
Time Frame
8 months
Secondary Outcome Measure Information:
Title
Efficacy assessment - OSDI-Ocular Surface Disease Index Questionnaire changes from baseline
Description
OSDI Score; 12 Questions; answers between 0-4; Total score calculated 0-100. Higher score means worst Dry Eye Symptomes
Time Frame
8 months
Title
Osmolarity mOsml/L
Description
Osmolarity test with TearLab
Time Frame
8 months
Title
Staining; Total Ocular Staining Score
Description
Corneal staining fluorescein and conjunctival/lid margin staining lissamine green
Time Frame
8 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
≥ 18 years
Mild to Moderate Periorbital wrinkles
OSDI score of at least 23
Noninvasive Tear film break up time (NIKBUT) ≤ 10 seconds
Willing and able to provide written informed consent.
Willing to participate in all study activities and instructions.
Exclusion Criteria:
Pregnancy and breastfeeding
Lesions in the periorbital area
Acute severe blepharitis
Acute conjunctivitis
Other concomitant anterior eye disease
Facility Information:
Facility Name
Vallmedic Vision & Aesthetic
City
Escaldes-Engordany
Country
Andorra
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Tixel Treatment for Dry Eye Symptoms
We'll reach out to this number within 24 hrs